Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06310876 · ClinicalTrials.gov registry record · Phase 1
A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects
A Phase 1 study of Healthy, sponsored by Calico Life Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT06310876 is a Phase 1 study of Healthy that has completed, run by Calico Life Sciences. The registered enrollment target is 72 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06310876, a Phase 1 study of Healthy, has completed, sponsored by Calico Life Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, blinded, placebo and active-controlled, 4-period, crossover design thorough QT/QTc (TQT) study to evaluate the effect of ABBV-CLS-7262 on cardiac repolarization in healthy adult subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ABBV-CLS-7262
- DRUG Moxifloxacin 400mg
Study Locations (1)
Illinois
- AbbVie Clinical Pharmacology Research Unit (ACPRU) - Grayslake
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-03-14 |
| Est. Completion | 2024-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06310876
The ClinicalTrials.gov registry entry for NCT06310876 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The listed sponsor is Calico Life Sciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06310876 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06310876 about?
NCT06310876 is a clinical study titled "A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects". This is a randomized, blinded, placebo and active-controlled, 4-period, crossover design thorough QT/QTc (TQT) study to evaluate the effect of ABBV-CLS-7262 on cardiac repolarization in healthy adult subjects.
What is the current status of trial NCT06310876?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2024-03-14. Estimated completion is 2024-06-26.
What conditions does trial NCT06310876 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT06310876?
The interventions under investigation include: Placebo (DRUG), ABBV-CLS-7262 (DRUG), Moxifloxacin 400mg (DRUG).
Who is sponsoring clinical trial NCT06310876?
This trial is sponsored by Calico Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06310876 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.